Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.
The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.
Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease.
The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Country | Israel |
| Founded | 2017 |
| IPO Date | Dec 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Alon Ben-Noon |
Contact Details
Address: Building B, 11 HaMenofim Street Herzliya, 4672562 Israel | |
| Phone | 972 9 799 6183 |
| Website | neurosense-tx.com |
Stock Details
| Ticker Symbol | NRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001875091 |
| CUSIP Number | M74240108 |
| ISIN Number | IL0011809592 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alon Ben-Noon | Chief Executive Officer |
| Or Eisenberg | Chief Financial Officer |
| Hagit Binder | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | F-3 | Filing |
| Dec 23, 2024 | 6-K | Report of foreign issuer |
| Dec 18, 2024 | 6-K | Report of foreign issuer |
| Dec 17, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | EFFECT | Notice of Effectiveness |
| Dec 12, 2024 | 424B3 | Prospectus |
| Dec 12, 2024 | D | Notice of Exempt Offering of Securities |
| Dec 11, 2024 | 6-K | Report of foreign issuer |
| Dec 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 6, 2024 | F-3 | Filing |